Compare Johnson & Johnson (JNJ) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.35 (market cap $323.80B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| JNJ | VEA | |
|---|---|---|
Market Cap | $618.09B | $323.80B |
Volume | 6,050,983 | 17,001,112 |
Sector | Health | — |
52-Week High | $278.43 | $73.79 |
52-Week Low | $186.00 | $58.90 |
Typical Hold Time | 129 Days | 131 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
VEA trades at $69.86, down 0.57% on the day, with a bearish technical signal from moving averages and oscillators. The ETF's low expense ratio of 0.03% and focus on developed markets outside the U.S. are key attributes, though financial ratios are not disclosed in the provided data. Recent news highlights institutional activity, with firms like Allianz Asset Management increasing positions while others reduced stakes.
The outlook for VEA is mixed, with technical indicators suggesting near-term pressure, but its cost efficiency and dividend yield offer long-term value. Risks include market volatility and economic shifts in developed economies. Investors should weigh the bearish technicals against the fund's structural advantages in a diversified portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
